Drugdocs | Vyepti

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Vyepti

Chemical Name	eptinezumab-jjmr
Dosage Form	Injectable (intravenous; 100 mg/mL)
Drug Class	Receptor antagonists
System	Nervous
Company	Lundbeck
Approval Year	2020

Indication

Vyepti is indicated for the preventive treatment of migraine in adults.

Last updated on 10/23/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Vyepti (eptinezumab-jjmr) Prescribing Information	2020	Lundbeck

Document Title	Year	Source
Small molecule calcitonin gene-related peptide receptor antagonists for the acute treatment of migraine.	2020	CADTH
Monoclonal antibodies to prevent migraine headaches.	2018	CADTH

Document Title	Year	Source
VA/DoD clinical practice guidelines: the primary care management of headache.	2020	U.S Department of Veteran Affairs